Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial DNA is a primary intracellular target for nitroimidazole antibiotics. These drugs are selectively toxic to anaerobic bacteria and certain protozoa because they require reductive activation to generate reactive intermediates that directly damage DNA, causing strand breaks and fragmentation. This process disrupts genetic integrity and leads to cell death.
Nitroimidazoles are reductively activated in anaerobic bacteria, forming reactive intermediates that cause DNA strand breaks and fragmentation, leading to loss of genetic integrity and cell death.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial genomic DNA (N/A).